Axogen (AXGN) Common Equity (2010 - 2026)

Axogen's Common Equity history runs 17 years deep, the most recent figure standing at $244.8 million for Q1 2026.

• On a quarterly basis, Common Equity rose 132.34% year-over-year to $244.8 million in Q1 2026; TTM through Mar 2026 was $244.8 million, a 132.34% increase from a year earlier, with the FY2025 full-year figure at $128.8 million, up 24.0% from the prior year.
• Common Equity rose to $244.8 million in Q1 2026 per AXGN's latest filing, from $128.8 million in the prior quarter.
• Across five years, Common Equity topped out at $244.8 million in Q1 2026 and bottomed at $93.2 million in Q1 2024.
• The 5-year median for Common Equity is $101.4 million (2022), against an average of $111.8 million.
• Across the five-year window, Common Equity dropped 14.33% in 2022 and surged 132.34% in 2026, its largest moves.
• Year by year, Common Equity stood at $101.0 million in 2022, then dropped by 5.28% to $95.7 million in 2023, then advanced by 8.62% to $103.9 million in 2024, then gained by 24.0% to $128.8 million in 2025, then soared by 90.0% to $244.8 million in 2026.
• Per Business Quant, the three latest AXGN Common Equity figures stand at $244.8 million (Q1 2026), $128.8 million (Q4 2025), and $120.8 million (Q3 2025).